---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-020128"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T19:19:36.264177+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Oragenics preparing Phase II trial for concussion drug ONP-002; secures CRO, optimizes formulation

## Summary
- ONP-002 intranasal neurosteroid for mild TBI (concussion) advances to Phase II after positive Phase I safety.
- Partnering with Avance Clinical for Phase IIa at level one trauma centers in Australia.
- Formulation optimized to increase active compound percentage and target brain absorption within minutes.
- Estimated 69 million concussion cases globally annually; up to 20% develop post-concussion syndrome.
- Adequate intranasal device supply secured for upcoming trial.

## SEC filing metadata
- accession: 0001493152-24-020128
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000149315224020128/0001493152-24-020128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000149315224020128/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-020128
- JSON: https://secwatch.observer/filing/0001493152-24-020128.json
- Plain text: https://secwatch.observer/filing/0001493152-24-020128.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.